Medical Marketing Moments

It's hard to believe that when this publication appeared 40 years ago, Tylenol was a relatively new product and the Medicare program was fresh out of the box. Of course, a lot has happened since then (not least to Tylenol and Medicare). Technology and the Internet have changed every facet of medical marketing, while regulatory shifts have opened the doors to DTC, and raised firewalls between education and promotion. MM&M has been there throughout, and we look forward to reporting on 40 more prosperous years for the industry.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.